Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 64, Issue 11, Pages 993-1004Publisher
ELSEVIER
DOI: 10.1016/j.addr.2012.01.007
Keywords
Prodrugs; Pt anticancer drugs; Ru anticancer drugs; Activation by reduction; Medicinal inorganic chemistry; Nanocarriers
Categories
Funding
- DAAD (German Academic Exchange Service)
- National Cancer Institute [CA034992]
Ask authors/readers for more resources
This review provides an overview of metal-based anticancer drugs and drug candidates. In particular, we focus on metal complexes that can be activated in the reducing environment of cancer cells, thus serving as prodrugs. There are many reports of Pt and Ru complexes as redox-activatable drug candidates, but other d-block elements with variable oxidation states have a similar potential to serve as prodrugs in this manner. In this context are compounds based on Fe, Co, or Cu chemistry, which are also covered. A trend in the field of medicinal inorganic chemistry has been toward molecularly targeted, metal-based drugs obtained by functionalizing complexes with biologically active ligands. Another recent activity is the use of nanomaterials for drug delivery, exploiting passive targeting of tumors with nano-sized constructs made from Au. Fe, carbon, or organic polymers. Although complexes of all of the above mentioned metals will be described, this review focuses primarily on Pt compounds, including constructs containing nanomaterials. (c) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available